免疫背景对接受基因型匹配靶向治疗的实体瘤患者结局的影响:一项综合性综述
本综述检索Web of Science、Medline和Embase,评估免疫背景对实体瘤基因型匹配靶向治疗结局(缓解、无进展生存、总生存)的影响,并对同一癌种同一免疫因子有3项及以上研究时行Meta分析、其余描述性分析。结果显示免疫背景在多个癌种中可预测靶向治疗获益差异。
要点
- BRAFV600E黑色素瘤术后辅助达拉非尼/曲美替尼时,免疫背景评估未凸显出不获益亚组。
- BRAFV600E结直肠癌高细胞溶解评分者从联合MEK抑制中获益,低评分者不加MEK抑制结局更好。
- 高PD-L1表达预测EGFR、ALK及G12C酪氨酸激酶抑制剂结局较差。
核心结论
- 据作者所知,这是首项评估免疫背景作为靶向治疗生物标志物的综述,其结果可作为未来转化研究推进分层精准肿瘤学的重要资源。
研究设计与样本
- 文献综述,检索Web of Science、Medline和Embase中评估免疫背景影响的研究,结局包括缓解、无进展生存和总生存。
- 数据取自多因素分析、单因素分析或直接取自Kaplan-Meier曲线。
- 同一癌种同一免疫因子有3项及以上研究时行Meta分析,其余研究行描述性分析。
主要发现
- 辅助治疗背景下,免疫背景评估未凸显出BRAFV600E黑色素瘤切除后使用达拉非尼/曲美替尼不获益的亚组。
- exceptional responders的差异基因表达显示免疫激活相关基因富集。
- 高细胞溶解评分的BRAFV600E结直肠癌患者从联合MEK抑制中获益,而低评分者不加MEK抑制结局更好。
- 高PD-L1表达预测EGFR、ALK和G12C酪氨酸激酶抑制剂结局较差;EGFR突变且高CD8+ T细胞和PD-L1阳性者结局极差。
- 基质肿瘤浸润淋巴细胞预测HER2阳性乳腺癌短程辅助曲妥珠单抗治疗中基质贫乏肿瘤的疗效;高免疫元基因和单免疫基因表达预测化疗联合曲妥珠单抗获益而非单纯化疗;在免疫非富集微环境中加用帕妥珠单抗或拉帕替尼似乎有益;高MHC-I对曲妥珠单抗为基础的治疗结局为负向预测,高MHC-II为正向预测。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Outcomes with genotype-matched targeted therapy in solid cancer patients are heterogeneous: some have exceptional responses, whereas others have primary progression. This review explores the immunobiological features which may underlie this differential response. METHODS: We conducted a literature review of studies assessing the impact of immune context following searches on Web of Science, Medline and Embase. Relevant outcomes include response, progression-free survival and overall survival. Data were extracted from multivariate analysis, univariate analysis or directly from Kaplan-Meier curves. Meta-analyses were carried out where three or more studies analysed the same immune factor for the same cancer type. The remaining studies were analysed descriptively. RESULTS: In the adjuvant setting, assessment of the immune context does not highlight a group failing to derive benefit for the use of dabrafenib/trametinib after resection of BRAFV600E melanoma. Differential gene expression in exceptional responders show enrichment of genes associated with immune activation. BRAFV600E colorectal cancer patients with high cytolytic scores benefit from the addition of MEK inhibition whereas those with low scores fare better without. High programmed death-ligand 1 (PD-L1) expression is predictive of inferior outcomes to epidermal growth factor receptor (EGFR), ALK and G12C tyrosine kinase inhibitors. EGFR-mutant patients with high CD8+ T cells and PD-L1 positivity have very poor outcomes. Stromal tumour-infiltrating lymphocytes predict for efficacy of stromal-poor tumours in human epidermal growth factor receptor 2 (HER2)-positive breast cancer treated with short-course adjuvant trastuzumab. High immune metagene and single immune gene expression are predictive of benefit for chemotherapy plus trastuzumab, but not chemotherapy alone. The addition of pertuzumab or lapatanib appears to be beneficial in those with immune non-enriched microenvironments. High major histocompatibility complex (MHC)-I is negatively predictive and high MHC-II is positively predictive of outcomes with trastuzumab-based therapy. CONCLUSIONS: To our knowledge, this is the first review assessing immunological context as a biomarker for targeted therapy. The results of this review represent an important resource to aid future translational studies in advancing stratified precision medicine oncology.
引用
- Mubarak O, Middleton GW. The impact of the immunological context on outcomes of solid cancer patients treated with genotype-matched targeted therapies: a comprehensive review. Ann Oncol. 2025. PMID: 40118150. doi:10.1016/j.annonc.2025.03.007
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。